Analysts at Robert W. Baird reiterated their Neutral rating and $55 price target on Biogen Idec Inc. (Nasdaq: BIIB) today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE